Advanced Filters
noise

endometrial-hyperplasia Clinical Trials

A listing of endometrial-hyperplasia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 17 clinical trials
C CHYONG-HUEY LAI, M.D.

Longitudinal Follow-up in Women With Endometrial Hyperplasia Without Atypia

This study will prospectively enroll a total of 1000 patients (200 per year) simple hyperplasia/complex hyperplasia (SH/CH) without atypia. All subjects will receive education for exercise and weight control and be randomized 1:1 to with or without metformin intervention. At the end of this 3-year project, an interim analysis will …

20 years of age Female Phase 3
J Jianliu Wang

Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.

17 - 45 years of age Female Phase 2
J Jianliu Wang

Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

To explore the treatment efficacy of Progesterone Therapeutic Regimen Plus Statins in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.

17 - 45 years of age Female Phase 2
Z Zheng Ying, professor

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

Primary end points: This clinical trial is aimed to analyze the effectiveness of Levonorgestrel-Releasing Intrauterine System (LNG-IUS, Mirena®) in the fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma, including pathology response and pregnancy outcome. Second end points: To analyze the appearances of side-effects.

- 40 years of age Female Phase 2/3
X Xiaojun Chen, PhD

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.

18 - 45 years of age Female Phase 2/3
X Xiaojun Chen, PhD

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.

18 - 45 years of age Female Phase 2/3
W WEIWEI SHAN, PhD

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.

18 - 45 years of age Female Phase 2/3
A Andrea Hagemann, M.D., MSCI

Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

The investigators hypothesize that combined treatment with the GLP-1R agonist semaglutide 2.4 mg and levonorgestrel intrauterine device (LNG-IUD), compared to LNG-IUD alone, will result in improved likelihood of uterine preservation, sustained weight loss, improved endometrial and metabolomic response to progestin, and improved quality of life in premenopausal women with endometrial …

18 - 45 years of age Female Phase 2
A Andrea Hagemann, M.D., MSCI

Uterine Preservation Via Lifestyle Transformation

Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal women has resulted in increasing rates of …

18 years of age Female Phase 2
L Li Yang

Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women

The goal of this clinical trial is to evaluate the effect and adverse side effects of membrane-inhibiting formula plus oral progestins as fertility-preserving treatment in patients with early-stage endometrial cancer and endometrial hyperplasia research questions:When taken with oral progestins, does the drug membrane-inhibiting formula shorten the time required for complete …

18 - 45 years of age Female Phase N/A

Simplify language using AI